Related Experiment Video
Updated: Feb 13, 2026

Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
Published on: July 14, 2023
Efficacy and safety of sarilumab in patients with active rheumatoid arthritis
Delilah McCarty1, April Robinson2
1Novo Nordisk Inc, 800 Scudders Mill Rd, Plainsboro, NJ 08536, USA.
Abstract:
The mainstay of rheumatoid arthritis (RA) treatment involves the use of medications that slow disease progression and reduce inflammation. Inadequate treatment responses and intolerances to conventional RA treatment have led to the development of biologic agents for the management of moderate-to-severe disease activity. Interleukin-6 (IL-6) inhibition is one of the targets for biologic activity in RA treatment. IL-6 is found in excess in the synovial fluid and contributes to joint erosion through its action on osteoclast cells. Sarilumab is a new IL-6 inhibitor indicated for the treatment of moderate-to-severe RA as monotherapy or in combination with conventional therapies in patients with an inadequate response to previous RA treatment.
Related Concept Videos
Survey Safety
Self-Efficacy
Household Wiring And Electrical Safety
Dose-Response Relationship: Potency and Efficacy
Patient-centered Care
Co-activators and Co-repressors

